Objectives: To externally validate the Barcelona Predictive Models (BCN-PM 1 and 2) for detecting csPCa in an Ibero-American population. BCN-PM 1 was designed to reduce magnetic resonance imaging (MRI) use, whereas BCN-PM 2 aims to decrease unnecessary prostate biopsies. Methods: This prospective, multicenter study included 661 men with suspected PCa recruited in 2025 across three Ibero-American centers. All participants underwent MRI followed by targeted biopsies of lesions with the Prostate Imaging–Reporting and Data System (PI-RADS) ≥ 3, along with systematic biopsy. When PI-RADS lesions were <3, only systematic biopsies were performed. CsPCa was defined as International Society of Urological Pathology Grade Group ≥ 2. BCN-PM 1 incorporates age (years), family history of PCa (no vs. yes), prior negative prostate biopsy (no vs. yes), digital rectal examination (DRE: normal vs. suspicious), and prostate volume-derived estimation by DRE (small, median, or large). BCN-PM 2 includes age, family history of PCa, prior negative prostate biopsy, prostate volume measured by MRI (mL), and PI-RADS score (1–5). Results: The rate of csPCa detection was 53.7%. Both models demonstrated good calibration with strong agreement between predicted probabilities and observed csPCa rates. BCN-PM 1 closely followed the reference line, with minor deviations at higher predicted probabilities, whereas BCN-PM 2 showed modest departures at the extremes of risk. The area under the curve was 0.740 (95% CI 0.702–0.777) for BCN-PM 1 and 0.803 (95% CI 0.769–0.836) for BCN-PM 2 (p < 0.001). Decision curve analysis demonstrated a net benefit for both models compared with strategies of biopsy in all or no men. BCN-PM 2 showed greater net benefit than BCN-PM 1. At 95% sensitivity, BCN-PM 1 reduced MRI requests by 10.6%, while BCN-PM 2 avoided 19.4% of unnecessary biopsies. The sequential use of BCN-PM 1 and 2 resulted in a 10.6% reduction in MRI exams and a 23.1% reduction in biopsies, at the cost of missing 8.4% of csPCa cases. The performance of the biopsy improved from 53.7% to 64.0% (p < 0.001). Conclusions: BCN-PM1 and BCN-PM 2 were successfully validated in an Ibero-American population.
Background: The ERSPC-MRI PM is of the most widely used and extensively validated predictive model in Europe. Objective: We aimed to validate and compare the perfor-mance of the BCN-MRI PM and ERSPC-MRI PM in an Ibero-American population. Met-hods: We conducted a prospective analysis of 540 men with suspected PCa who underwent MRI and prostate biopsy in 2025. Individual csPCa risk estimates were cal-culated using the online calculators for the BCN-MRI PM and ERSPC-MRI PM. Results: The overall csPCa detection rate was 55.7%. The BCN-MRI PM demonstrated good cali-bration, with close agreement between predicted and observed csPCa probabilities, whereas the ERSPC-MRI PM underestimated risk in the intermediate-probability range. Discrimination for csPCa was significantly better with the BCN-MRI PM (AUC, 0.807; 95% CI 0.771-0.843) than with the ERSPC-MRI PM (AUC, 0.764; 95% CI 0.724-0.803; p < 0,001). Decision curve analysis showed a greater net benefit for the BCN-MRI PM than for the ERSPC-MRI PM and the strategy of biopsying all men. Clinical utility curves demon-strated a more favorable balance between avoided biopsies and missed csPCa cases across threshold probabilities. At a sensitivity of 95%, the BCN-MRI PM achieved a specificity of 38.9% (95% CI, 32.5%–45.1%) compared with 30.1% (95% CI, 24.6%–35.7%) for the ERSPC-MRI PM, avoiding 21.5% and 16.3% of biopsies, respectively (p = 0.043). The performance of both models was also evaluated according to PI-RADS category and participating center. Conclusions: In this Ibero-American cohort, the BCN-MRI PM demonstrated superior calibration and overall clinical performance compared with the ERSPC-MRI PM.
Background: External validation of predictive models is needed in new populations after their implementation. Objective: We aimed to validate and compare the performance of the BCN-MRI PM and ERSPC-MRI PM in an Ibero-American population. Methods: We conducted a retrospective analysis of 540 men with suspected PCa who underwent MRI and prostate biopsy in 2025. Individual csPCa risk estimates were calculated using the online calculators for the BCN-MRI PM and ERSPC-MRI PM. The reference standard outcome was the rate of avoided biopsies. Calibration, discrimination of csPCa, net benefit, and clinical utility were analyzed with R software. Results: All participants underwent MRI and prostate biopsy. The median age was 66 years (95% CI 61–71). The overall csPCa detection rate was 55.7%. The BCN-MRI PM demonstrated good calibration, with close agreement between predicted and observed csPCa probabilities, whereas the ERSPC-MRI PM underestimated risk in the intermediate-probability range. Discrimination for csPCa was significantly better with the BCN-MRI PM (AUC, 0.807; 95% CI 0.771–0.843) than with the ERSPC-MRI PM (AUC, 0.764; 95% CI 0.724–0.803; p < 0.001). Decision curve analysis showed a greater net benefit for the BCN-MRI PM than for the ERSPC-MRI PM and the strategy of biopsying all men. Clinical utility curves demonstrated a more favorable balance between avoided biopsies and missed csPCa cases across threshold probabilities. At a sensitivity of 95%, the BCN-MRI PM achieved a specificity of 38.9% (95% CI, 32.5–45.1%) compared with 30.1% (95% CI, 24.6–35.7%) for the ERSPC-MRI PM, avoiding 21.5% and 16.3% of biopsies, respectively (p = 0.043). The performance of both models was also evaluated according to PI-RADS category and participating center. Conclusions: In this Ibero-American cohort, the BCN-MRI PM demonstrated superior calibration and overall clinical performance compared with the ERSPC-MRI PM.